These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27066860)

  • 21. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
    Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
    Canuso CM; Grinspan A; Kalali A; Damaraju CV; Merriman U; Alphs L; Awad AG
    Int Clin Psychopharmacol; 2010 May; 25(3):155-64. PubMed ID: 20216424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program.
    Andorn A; Graham J; Csernansky J; Newcomer JW; Shinde S; Muma G; Heidbreder C; Fava M
    J Clin Psychopharmacol; 2019; 39(5):428-433. PubMed ID: 31343440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients.
    Le Moigne A; Csernansky J; Leadbetter RA; Andorn AC; Graham JA; Heath AT; Walling DP; Newcomer JW; Marder SR
    J Clin Psychiatry; 2021 Sep; 82(5):. PubMed ID: 34551218
    [No Abstract]   [Full Text] [Related]  

  • 31. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
    Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P
    Am J Psychiatry; 1998 Apr; 155(4):499-504. PubMed ID: 9545995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
    Kane JM; Harary E; Eshet R; Tohami O; Weiser M; Leucht S; Merenlender-Wagner A; Sharon N; Davis GL; Suett M; Franzenburg KR; Correll CU
    Lancet Psychiatry; 2023 Dec; 10(12):934-943. PubMed ID: 37924833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
    Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
    Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.